Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADI NASDAQ:BCDA NASDAQ:BLUE NASDAQ:ONCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$1.81-0.5%$1.82$1.21▼$3.81$44.70M0.68261,100 shs126,561 shsBCDABioCardia$2.04$2.06$1.63▼$3.26$11.83M0.8564,946 shs18,398 shsBLUEbluebird bio$4.97$4.78$3.20▼$25.10$48.67M0.27452,966 shsN/AONCYOncolytics Biotech$1.08-6.9%$1.03$0.33▼$1.53$116.42M1.19680,065 shs1.19 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience+0.83%+0.55%+4.60%+7.69%+4.60%BCDABioCardia+3.03%+5.15%+4.08%-4.23%-28.92%BLUEbluebird bio0.00%0.00%0.00%0.00%-56.20%ONCYOncolytics Biotech+0.87%+9.43%+31.36%+248.56%+22.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$1.81-0.5%$1.82$1.21▼$3.81$44.70M0.68261,100 shs126,561 shsBCDABioCardia$2.04$2.06$1.63▼$3.26$11.83M0.8564,946 shs18,398 shsBLUEbluebird bio$4.97$4.78$3.20▼$25.10$48.67M0.27452,966 shsN/AONCYOncolytics Biotech$1.08-6.9%$1.03$0.33▼$1.53$116.42M1.19680,065 shs1.19 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience+0.83%+0.55%+4.60%+7.69%+4.60%BCDABioCardia+3.03%+5.15%+4.08%-4.23%-28.92%BLUEbluebird bio0.00%0.00%0.00%0.00%-56.20%ONCYOncolytics Biotech+0.87%+9.43%+31.36%+248.56%+22.08%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M1.78N/AN/A$4.29 per share0.42BCDABioCardia$60K197.20N/AN/A$0.18 per share11.33BLUEbluebird bio$103.95M0.47N/AN/A$35.59 per share0.14ONCYOncolytics BiotechN/AN/AN/AN/A$0.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%11/4/2025 (Estimated)BCDABioCardia-$7.95M-$1.85N/AN/AN/AN/A-19,117.42%-246.92%11/11/2025 (Estimated)BLUEbluebird bio-$211.91M-$41.32N/AN/AN/A-565.74%-322.46%-53.17%N/AONCYOncolytics Biotech-$23.14M-$0.27N/AN/AN/AN/A-438.11%-143.90%11/11/2025 (Estimated)Latest BCDA, ONCY, BLUE, and AADI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025BCDABioCardia-$0.50-$0.40+$0.10-$0.40N/AN/A8/8/2025Q2 2025ONCYOncolytics Biotech-$0.11-$0.05+$0.06-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54BCDABioCardiaN/A0.330.33BLUEbluebird bio0.370.510.33ONCYOncolytics BiotechN/A2.882.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%BCDABioCardia20.57%BLUEbluebird bio87.43%ONCYOncolytics Biotech6.82%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%BCDABioCardia20.00%BLUEbluebird bio1.40%ONCYOncolytics Biotech0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionOptionableBCDABioCardia405.80 million4.64 millionOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableONCYOncolytics Biotech30100.36 million100.26 millionNot OptionableBCDA, ONCY, BLUE, and AADI HeadlinesRecent News About These CompaniesOncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal TumorsSeptember 2 at 9:10 AM | prnewswire.comCancer Treatment Revolution Drives $903B Market as New Therapies Gain MomentumAugust 28, 2025 | baystreet.caOncolytics Biotech® Announces Upcoming Investor Conferences in SeptemberAugust 28, 2025 | prnewswire.comHere's Why We're Watching Oncolytics Biotech's (NASDAQ:ONCY) Cash Burn SituationAugust 27, 2025 | finance.yahoo.comOncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Recommendation of "Moderate Buy" from AnalystsAugust 26, 2025 | marketbeat.comOncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAugust 24, 2025 | americanbankingnews.comOncolytics Biotech (NASDAQ:ONCY) Raised to Hold at Wall Street ZenAugust 17, 2025 | marketbeat.comLake Street Capital Begins Coverage on Oncolytics Biotech (NASDAQ:ONCY)August 15, 2025 | marketbeat.comLake Street Initiates Coverage of Oncolytics Biotech (ONCY) with Buy RecommendationAugust 14, 2025 | msn.comOncolytics Biotech Inc.: Oncolytics Biotech Announces Voting Results from the Annual General Meeting of ShareholdersAugust 12, 2025 | finanznachrichten.deOncolytics Biotech® Announces Voting Results from the Annual General Meeting of ShareholdersAugust 11, 2025 | prnewswire.comOncolytics Biotech (NASDAQ:ONCY) Issues Quarterly Earnings ResultsAugust 11, 2025 | marketbeat.comJonesTrading Remains a Hold on Oncolytics Biotech (ONCY)August 10, 2025 | theglobeandmail.comOncolytics Biotech Inc.: Oncolytics Biotech Reports Second Quarter Financial Results and Details Clinical Program Plans for PelareorepAugust 8, 2025 | finanznachrichten.deOncolytics Biotech Inc.: Oncolytics Biotech Announces Voluntary Delisting from the Toronto Stock ExchangeAugust 8, 2025 | finanznachrichten.deOncolytics Biotech Files SEC Report Incorporating Information CircularAugust 8, 2025 | tipranks.comOncolytics Biotech Reports Reduced Losses in Q2 2025 Financial UpdateAugust 8, 2025 | tipranks.comOncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for PelareorepAugust 8, 2025 | prnewswire.comOncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock ExchangeAugust 8, 2025 | prnewswire.comWhat to Expect from Oncolytics Biotech's EarningsAugust 7, 2025 | benzinga.comOncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial ResultsAugust 5, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCDA, ONCY, BLUE, and AADI Company DescriptionsAadi Bioscience NASDAQ:AADI$1.81 -0.01 (-0.55%) As of 09/3/2025Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.BioCardia NASDAQ:BCDA$2.04 0.00 (0.00%) Closing price 03:59 PM EasternExtended Trading$2.01 -0.03 (-1.47%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.bluebird bio NASDAQ:BLUEbluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Oncolytics Biotech NASDAQ:ONCY$1.08 -0.08 (-6.90%) Closing price 04:00 PM EasternExtended Trading$1.13 +0.05 (+4.54%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
